Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,839 companies covered, latest filing Oct 23.

  • $1.5B bought by 343 insiders at 210 companies
  • $3.2B sold by 267 insiders outside a trading plan
  • $7.9B sold by 827 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past month, each insider's filings added up.

  1. LENLennar
    Berkshire Hathaway Inc.10% owner, +1 joint filer
    4,758,747 shares at $80.46 Sep 23–Oct 2, 3 filings 3 superinvestors bought in Q2
    $383M
  2. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    6,596,299 shares at $34.18 Sep 21–Oct 20, 21 filings +5.3% to stake 2 superinvestors bought in Q2
    $225M
  3. KODKodiak Sciences
    Baker Bros. Advisors LPDirector, +5 joint filers
    1,941,755 shares at $80.85 Sep 28–29, 3 filings +11% to stake 1 superinvestor sold in Q2
    $157M
  4. SAFXXCF Global
    EEME Energy SPV I, LLC10% owner
    119M shares at $1.19 Oct 16 +109% to stake
    $142M
  5. GPIGroup 1 Automotive
    Conifer Management, L.L.C.10% owner
    400,000 shares at $244.51 Sep 24–30, 2 filings +26% to stake 2 superinvestors bought in Q2
    $97.8M
  6. UUUUniversal Safety Products
    Milton C Ault IIIDirector
    33,434 shares at $2,766.36 Sep 21–30, 2 filings
    $92.5M
  7. GMEGameStop
    Ryan CohenCEO
    1,994,130 shares at $25.29 Sep 29–Oct 13, 3 filings +4.9% to stake
    $50.4M
  8. BORRBorr Drilling
    Tor Olav TroimDirector
    9,500,000 shares at $4.53 Oct 5–15, 7 filings +31% to stake
    $43M
  9. PAMPampa Energia
    Marcos Marcelo MindlinDirector
    435,000 shares at $80.78 Oct 15 +6.4% to stake
    $35.1M
  10. GGRGogoro
    Chung-Yao YinDirector
    14.2M shares at $2.48 Oct 7 New stake
    $35.1M

Biggest sales

Past month, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    86,222 shares at $48,532.59 Oct 7–20, 2 filings 1.1% of stake Planned sale (10b5-1)
    $4.2B
  2. MDLNMedline
    GIC Private Ltd10% owner, +2 joint filers
    28.5M shares at $34.97 Oct 2–8, 2 filings
    $996M
  3. ESTCElastic
    Steven SchuurmanDirector
    3,500,000 shares at $92.43 Oct 5–12, 2 filings 58% of stake
    $323M
  4. TALOTalos Energy
    Empresarial De Capitales S.a. De C.v. Control10% owner
    14.6M shares at $17.33 Oct 6–19, 5 filings 37% of stake
    $253M
  5. AVGOBroadcom
    Henry SamueliDirector
    702,190 shares at $356.04 Sep 23 1.9% of stake Planned sale (10b5-1)
    $250M
  6. THTarget Hospitality
    TDR Capital II Investments LP10% owner, +9 joint filers
    11M shares at $18.40 Oct 1 40% of stake
    $202M
  7. ANETArista Networks
    Jayshree UllalCEO
    778,531 shares at $213.68 Sep 25–Oct 9, 4 filings 4.8% of stake Planned sale (10b5-1)
    $166M
  8. KNTKKinetik
    ISQ Global Fund II GP LLC10% owner, +4 joint filers
    2,448,272 shares at $54.63 Sep 22–Oct 13, 4 filings 100% of stake
    $134M
  9. CRWDCrowdStrike
    Burt W. PodbereCFO
    480,000 shares at $261.44 Sep 24 Planned sale (10b5-1)
    $125M
  10. NBISNebius Group
    Ophir NaveCOO
    500,000 shares at $235.53 Oct 5 52% of stake Planned sale (10b5-1)
    $118M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 5 insiders, $1.6M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +1 more

    Latest buy Oct 22 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

PAHC insider trades

Every open-market buy and sale in PAHC, one row per filing, newest first

PAHC page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1M 18,608 shares at $54.61 25% of stake
    Traded May 5–7 Filed May 7
    ↗
  2. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1.1M 21,120 shares at $53.86 22% of stake
    Traded Apr 28–30 Filed Apr 30
    ↗
  3. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1.2M 21,120 shares at $54.79 18% of stake
    Traded Apr 21–23 Filed Apr 23
    ↗
  4. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1.2M 21,120 shares at $56.89 15% of stake
    Traded Apr 14–16 Filed Apr 16
    ↗
  5. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $757K 14,080 shares at $53.75 27% of stake
    Traded Mar 30–31 Filed Mar 31
    ↗
  6. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1.2M 21,120 shares at $55.21 29% of stake
    Traded Mar 24–26 Filed Mar 26
    ↗
  7. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1.2M 22,880 shares at $52.40 24% of stake
    Traded Mar 17–19 Filed Mar 19
    ↗
  8. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $258K 5,280 shares at $48.91 5.2% of stake
    Traded Mar 13 Filed Mar 16
    ↗
  9. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1.1M 21,120 shares at $52.27 94% of stake
    Traded Feb 24–26 Filed Feb 26
    ↗
  10. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $716K 14,080 shares at $50.84 38% of stake
    Traded Feb 19–20 Filed Feb 23
    ↗
  11. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $728K 14,080 shares at $51.68 28% of stake
    Traded Feb 13–18 Filed Feb 18
    ↗
  12. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $3.7M 72,198 shares at $51.77 59% of stake
    Traded Feb 10–11 Filed Feb 11
    ↗
  13. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $5.4M 110,842 shares at $48.38 47% of stake
    Traded Feb 5 Filed Feb 9
    ↗
  14. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $545K 13,180 shares at $41.39 21% of stake
    Traded Feb 3–4 Filed Feb 5
    ↗
  15. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $540K 13,465 shares at $40.11 30% of stake
    Traded Jan 29–30 Filed Feb 2
    ↗
  16. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $50K 1,235 shares at $40.55 7.4% of stake
    Traded Jan 23 Filed Jan 27
    ↗
  17. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1.2M 27,845 shares at $41.82 63% of stake
    Traded Jan 21–22 Filed Jan 22
    ↗
  18. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $570K 14,134 shares at $40.31 24% of stake
    Traded Jan 13–15 Filed Jan 15
    ↗
  19. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $8,554 213 shares at $40.16 0.5% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  20. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $13K 328 shares at $40.09 0.8% of stake
    Traded Jan 7 Filed Jan 8
    ↗
  21. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $235K 5,752 shares at $40.93 13% of stake
    Traded Dec 11, 2025 Filed Dec 15, 2025
    ↗
  22. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $193K 4,808 shares at $40.10 9.7% of stake
    Traded Dec 8–9 Filed Dec 10, 2025
    ↗
  23. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $289K 7,040 shares at $41.00 12% of stake
    Traded Dec 3–4 Filed Dec 4, 2025
    ↗
  24. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $296K 7,040 shares at $42.10 21% of stake
    Traded Nov 28, 2025–Dec 1, 2025 Filed Dec 2, 2025
    ↗
  25. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $542K 12,320 shares at $43.97 27% of stake
    Traded Nov 25–26 Filed Nov 26, 2025
    ↗
  26. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $147K 3,520 shares at $41.76 7.1% of stake
    Traded Nov 20, 2025 Filed Nov 24, 2025
    ↗
  27. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $467K 10,560 shares at $44.19 18% of stake
    Traded Nov 17–18 Filed Nov 18, 2025
    ↗
  28. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1.4M 30,337 shares at $45.01 85% of stake
    Traded Nov 12–13 Filed Nov 13, 2025
    ↗
  29. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $1.9M 41,823 shares at $45.09 67% of stake
    Traded Nov 7–10 Filed Nov 10, 2025
    ↗
  30. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $297K 7,040 shares at $42.16 10% of stake
    Traded Nov 4–5 Filed Nov 6, 2025
    ↗
  31. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $437K 10,560 shares at $41.43 19% of stake
    Traded Oct 28–30 Filed Oct 30, 2025
    ↗
  32. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $766K 18,899 shares at $40.53 26% of stake
    Traded Oct 22–24 Filed Oct 24, 2025
    ↗
  33. Jack Bendheim CEO, +1 joint filer
    PAHCPhibro Animal Health
    Planned sale
    $677K 16,775 shares at $40.37 41% of stake
    Traded Oct 17–20 Filed Oct 21, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.